Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model

Oncology Letters

Volumn 6, Issue 4, 2013, Pages 933-938

  Cho, Kang Su ^a   Yoon, So Jung ^a   Lee, Joo Yong ^a   Cho, Nam Hoon ^b   Choi, Young Deuk ^a   Song, Yun Seob ^c   Hong, Sung Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Chemokine; CXCL12; CXCR4; Prostatic neoplasms; Receptors

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; PLERIXAFOR; PROTEIN KINASE B;

ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84881608628     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1515     Document Type: Article

References (38)

1. No authors listed: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med311: 1281-1286, 1984.
2. Gittes RF: Carcinoma of the prostate. N Engl J Med324: 236-245, 1991.
3. Wirth MP: Hormone-refractory prostate cancer: what have we learned? BJU Int 100 (Suppl2): 56-59, 2007.
4. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T and HonjoT: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261: 600-603, 1993.
5. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A and SpringerTA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184: 1101-1109, 1996.
6. Wells TN, Power CA, Lusti-Narasimhan M, et al: Selectivity and antagonism of chemokine receptors. J Leukoc Biol 59: 53-60, 1996.
7. Zlotnik A: Chemokines and cancer. Int J Cancer 119: 2026-2029, 2006.
8. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
9. Furusato B, Mohamed A, Uhlen M and Rhim JS: CXCR4 and cancer. Pathol Int 60: 497-505, 2010.
10. Sun YX, Wang J, Shelburne CE, et al: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89: 462-473, 2003.
11. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y and FuseH: Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99: 539-542, 2008.
12. Darash-Yahana M, Pikarsky E, Abramovitch R, et al: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18: 1240-1242, 2004.
13. Smart EJ and Anderson RG: Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol353: 131-139, 2002.
14. Kucia M, Reca R, Miekus K, et al: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23: 879-894, 2005.
15. Wang J, Wang J, Sun Y, et al: Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 17: 1578-1592, 2005.
16. Chinni SR, Sivalogan S, Dong Z, et al: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate66: 32-48, 2006.
17. Singh S, Singh UP, Grizzle WE and Lillard JWJr: CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest84: 1666-1676, 2004.
18. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K and AgrawalKC: Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res65: 9891-9898, 2005.
19. Okera M, Bae K, Bernstein E, et al: Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int 108: E51-E58, 2011.
20. Wang Q, Diao X, Sun J and Chen Z: Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 35: 897-904, 2011.
21. Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 13: 1561-1568, 2007.
22. Libura J, Drukala J, Majka M, et al: CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100: 2597-2606, 2002.
23. Mori T, Doi R, Koizumi M, et al: CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 3: 29-37, 2004.
24. Hong X, Jiang F, Kalkanis SN, et al: SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion. Cancer Lett 236: 39-45, 2006.
25. Gilbert DC, Chandler I, McIntyre A, et al: Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 217: 94-102, 2009.
26. Kijima T, Maulik G, Ma PC, et al: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62: 6304-6311, 2002.
27. Li JK, Yu L, Shen Y, Zhou LS, Wang YC and Zhang JH: Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol14: 2308-2313, 2008.
28. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A and KikkawaF: Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122: 91-99, 2008.
29. Sehgal A, Keener C, Boynton AL, Warrick J and Murphy GP: CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 69: 99-104, 1998.
30. Sehgal A, Ricks S, Boynton AL, Warrick J and MurphyGP: Molecular characterization of CXCR-4: a potential brain tumor-associated gene. J Surg Oncol 69: 239-248, 1998.
31. Uchida D, Onoue T, Tomizuka Y, et al: Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma. Mol Cancer Res 5: 685-694, 2007.
32. Kreisberg JI, Malik SN, Prihoda TJ, et al: Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236, 2004.
33. Ayala G, Thompson T, Yang G, et al: High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10: 6572-6578, 2004.
34. Rubin JB, Kung AL, Klein RS, et al: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100: 13513-13518, 2003.
35. De Falco V, Guarino V, Avilla E, et al: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67: 11821-11829, 2007.
36. Yoon Y, Liang Z, Zhang X, et al: CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res67: 7518-7524, 2007.
37. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121: 335-348, 2005.
38. Hendrix CW, Collier AC, Lederman MM, et al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262, 2004.